{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:55:34Z","timestamp":1788612934203,"version":"build-2803163510"},"reference-count":13,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,13]]},"abstract":"<jats:p>Betibeglogene autotemcel (beti-cel) gene therapy (GT) for patients with transfusion-dependent \u03b2-thalassemia uses autologous CD34+ cells transduced with BB305 lentiviral vector (LVV), which encodes a modified \u03b2-globin gene. BB305 LVV also contains select HIV sequences for viral packaging, reverse transcription, and integration. This case report describes a patient successfully treated with beti-cel in a phase 1\/2 study (HGB-204; #NCT01745120) and subsequently diagnosed with wild-type (WT) HIV infection. From 3.5 to 21 months postinfusion, the patient stopped chronic red blood cell transfusions; total hemoglobin (Hb) and GT-derived HbAT87Q levels were 6.6 to 9.5 and 2.8 to 3.8 g\/dL, respectively. At 21 months postinfusion, the patient resumed transfusions for anemia that coincided with an HIV-1 infection diagnosis. Quantitative polymerase chain reaction assays detected no replication-competent lentivirus. Next-generation sequencing confirmed WT HIV sequences. Six months after starting antiretroviral therapy, total Hb and HbAT87Q levels recovered to 8.6 and 3.6 g\/dL, respectively, and 3.5 years postinfusion, 13.4 months had elapsed since the patient\u2019s last transfusion. To our knowledge, this is the first report of WT HIV infection in an LVV-based GT recipient and demonstrates persistent long-term hematopoiesis after treatment with beti-cel and the ability to differentiate between WT HIV and BB305-derived sequences.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003680","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T11:51:03Z","timestamp":1625140263000},"page":"2701-2706","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Wild-type HIV infection after treatment with lentiviral gene therapy for \u03b2-thalassemia"],"prefix":"10.1182","volume":"5","author":[{"given":"Suradej","family":"Hongeng","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2791-7471","authenticated-orcid":false,"given":"Usanarat","family":"Anurathapan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duantida","family":"Songdej","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2474-1850","authenticated-orcid":false,"given":"Angsana","family":"Phuphuakrat","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesinee","family":"Jongrak","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Parsons","sequence":"additional","affiliation":[{"name":"bluebird bio, Inc., Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana","family":"Deary","sequence":"additional","affiliation":[{"name":"bluebird bio, Inc., Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Bonner","sequence":"additional","affiliation":[{"name":"bluebird bio, Inc., Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Veres","sequence":"additional","affiliation":[{"name":"bluebird bio, Inc., Cambridge, MA;"},{"name":"BioMarin Pharmaceutical Inc., San Rafael, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Asmal","sequence":"additional","affiliation":[{"name":"bluebird bio, Inc., Cambridge, MA;"},{"name":"OrbiMed Advisors, LLC, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"issue":"16","key":"2021070115350825200_B1","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent \u03b2-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N Engl J Med."},{"issue":"9","key":"2021070115350825200_B2","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N Engl J Med."},{"issue":"12","key":"2021070115350825200_B3","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/JOM.0000000000000879","article-title":"Risks associated with lentiviral vector exposures and prevention strategies","volume":"58","author":"Schlimgen","year":"2016","journal-title":"J Occup Environ Med."},{"issue":"2","key":"2021070115350825200_B4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/hum.2016.007","article-title":"Gene therapy of the \u03b2-hemoglobinopathies by lentiviral transfer of the \u03b2A(T87Q)-globin gene","volume":"27","author":"Negre","year":"2016","journal-title":"Hum Gene Ther."},{"issue":"7313","key":"2021070115350825200_B5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature."},{"issue":"2","key":"2021070115350825200_B6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1128\/mr.55.2.193-205.1991","article-title":"Genetic regulation of human immunodeficiency virus","volume":"55","author":"Steffy","year":"1991","journal-title":"Microbiol Rev."},{"key":"2021070115350825200_B7","author":"Centers for Disease Control and Prevention","year":"2018"},{"issue":"1","key":"2021070115350825200_B8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1566523214666141127095336","article-title":"Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of \u03b2-thalassemia and sickle cell disease","volume":"15","author":"Negre","year":"2015","journal-title":"Curr Gene Ther."},{"issue":"1","key":"2021070115350825200_B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.biochem.67.1.1","article-title":"HIV-1: fifteen proteins and an RNA","volume":"67","author":"Frankel","year":"1998","journal-title":"Annu Rev Biochem."},{"issue":"21","key":"2021070115350825200_B10","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1001\/jama.1989.03420210052015","article-title":"Serum immunoreactive erythropoietin in HIV-infected patients","volume":"261","author":"Spivak","year":"1989","journal-title":"JAMA."},{"issue":"6","key":"2021070115350825200_B11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41573-019-0020-9","article-title":"Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges","volume":"18","author":"Cavazzana","year":"2019","journal-title":"Nat Rev Drug Discov."},{"issue":"2","key":"2021070115350825200_B12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/mt.2013.296","article-title":"False-positive HIV PCR test following ex vivo lentiviral gene transfer treatment of X-linked severe combined immunodeficiency vector","volume":"22","author":"De Ravin","year":"2014","journal-title":"Mol Ther."},{"issue":"13","key":"2021070115350825200_B13","doi-asserted-by":"crossref","first-page":"8410","DOI":"10.1128\/JVI.79.13.8410-8421.2005","article-title":"Mobilization and mechanism of transcription of integrated self-inactivating lentiviral vectors","volume":"79","author":"Hanawa","year":"2005","journal-title":"J Virol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/13\/2701\/1811177\/advancesadv2020003680.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/13\/2701\/1811177\/advancesadv2020003680.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T11:51:14Z","timestamp":1625140274000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/13\/2701\/476245\/Wild-type-HIV-infection-after-treatment-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":13,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,7,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003680","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]}}}